SynthesisBMC pregnancy and childbirth2026
Genetic diagnosis in fetuses with biliary tract system abnormalities: a meta-analysis and systematic review.
Synthesis in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundBiliary tract system (BTS) anomalies in fetuses are rare, but carry a wide range of clinical prognoses. The present meta-analysis aims to determine the prevalence and spectrum of genetic etiologies in fetuses with BTS anomalies and evaluate their clinical implications.
methodsPubMed and Ovid Medline were searched up to June 2025. Studies reporting prenatal genetic results and outcomes of fetuses with BTS anomalies were included. The spectrum of genetic etiologies detected across included studies was systematically summarized. Pooled prevalence of genetic etiology was calculated using random-effects models, with stratified analyses by isolation status, associated anomaly types, specific BTS phenotypes, genetic testing methods, and abnormality categories. We also assessed the incidence of biliary atresia (BA) in fetuses with normal genetic test results.
resultsSeventeen studies comprising 1,105 fetuses were included. The pooled prevalence of genetic etiology was 9.1% (95% CI, 3.3-16.4%). The risk differed sharply between isolated versus nonisolated status: 0% (95% CI, 0.0-0.2%) in isolated and 32.6% (95% CI, 18.1-48.6%) in nonisolated cases. Among genetically positive cases, numerical chromosomal abnormalities (including aneuploidies and triploidies) accounted for 41.3% (mainly trisomy 18), chromosomal structural abnormalities (including copy number variations, CNVs) accounted for 33.6%, and monogenic disorders (e.g., cystic fibrosis, CF) for 25.0%. The detection rate was higher with chromosomal microarray analysis (CMA)/copy number variation sequencing (CNV-seq) than with karyotype alone (13.5% vs. 9.4%). In fetuses with normal genetic results, postnatal BA occurred in 1.1% (95% CI, 0.0%-8.5%) of the nonisolated group and 0.0% (95% CI, 0.0%-1.3%) of the isolated group.
conclusionsIn fetal BTS anomalies, genetic risk depends largely on associated findings. The 0% diagnostic yield in isolated cases comes mainly from karyotyping and CMA; sequencing was rarely used, so rare monogenic disorders cannot be fully excluded. Nonisolated cases carry a high probability of genetic anomalies and benefit from genetic evaluation. Postnatal surveillance for BA is still needed even with normal genetic results.
trial registrationNot applicable. This systematic review and meta-analysis was registered in PROSPERO (CRD420251128401).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.